Sunshine Biopharma Inc (SBFM) FinancialsSBFMFinancialSunshine Biopharma Inc

Evaluating the bottom line, Sunshine Biopharma Inc maintains a gross margin of 25.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.41%, while the net margin is -16.88%. These profitability ratios, combined with a Return on Equity (ROE) of -21.93%, provide a clear picture of how effectively SBFM converts its operational activities into shareholder value.

In the context of the broader market, SBFM competes directly with industry leaders such as INM and GLMD. With a market capitalization of $4.46M, it holds a significant position in the sector. When comparing efficiency, SBFM's gross margin of 25.35% stands against INM's N/A and GLMD's N/A. Such benchmarking helps identify whether Sunshine Biopharma Inc is trading at a premium or discount relative to its financial performance.

The company reported total revenue of $9,263,687 in Q2 2026, but continues to face net losses, with a net income of -1,564,048 in the same quarter. The gross margin has been declining, currently at 25.35%.